NO951613L - Ikke-peptidyl tachykinin reseptorantagonister - Google Patents
Ikke-peptidyl tachykinin reseptorantagonisterInfo
- Publication number
- NO951613L NO951613L NO951613A NO951613A NO951613L NO 951613 L NO951613 L NO 951613L NO 951613 A NO951613 A NO 951613A NO 951613 A NO951613 A NO 951613A NO 951613 L NO951613 L NO 951613L
- Authority
- NO
- Norway
- Prior art keywords
- receptor antagonists
- tachykinin receptor
- substituted
- peptidyl tachykinin
- benzylmidazoles
- Prior art date
Links
- 239000002462 tachykinin receptor antagonist Substances 0.000 title abstract 2
- 241000124008 Mammalia Species 0.000 abstract 1
- 102000003141 Tachykinin Human genes 0.000 abstract 1
- 239000003085 diluting agent Substances 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 239000000546 pharmaceutical excipient Substances 0.000 abstract 1
- 108060008037 tachykinin Proteins 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
- C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
- C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D231/12—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A61K31/427—Thiazoles not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
- C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
- C07D233/56—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, attached to ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
- C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
- C07D235/04—Benzimidazoles; Hydrogenated benzimidazoles
- C07D235/06—Benzimidazoles; Hydrogenated benzimidazoles with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached in position 2
- C07D235/08—Radicals containing only hydrogen and carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
- C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
- C07D235/04—Benzimidazoles; Hydrogenated benzimidazoles
- C07D235/18—Benzimidazoles; Hydrogenated benzimidazoles with aryl radicals directly attached in position 2
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
- C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
- C07D249/08—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pain & Pain Management (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US23540194A | 1994-04-29 | 1994-04-29 |
Publications (2)
Publication Number | Publication Date |
---|---|
NO951613D0 NO951613D0 (no) | 1995-04-27 |
NO951613L true NO951613L (no) | 1995-10-30 |
Family
ID=22885338
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
NO951613A NO951613L (no) | 1994-04-29 | 1995-04-27 | Ikke-peptidyl tachykinin reseptorantagonister |
Country Status (18)
Country | Link |
---|---|
EP (1) | EP0694535A1 (fr) |
JP (1) | JPH08109169A (fr) |
KR (1) | KR950031074A (fr) |
CN (1) | CN1113236A (fr) |
AU (1) | AU1765695A (fr) |
BR (1) | BR9501770A (fr) |
CA (1) | CA2148053A1 (fr) |
CO (1) | CO4560552A1 (fr) |
CZ (1) | CZ104795A3 (fr) |
FI (1) | FI952064A (fr) |
HU (1) | HUT70637A (fr) |
IL (1) | IL113472A0 (fr) |
NO (1) | NO951613L (fr) |
NZ (1) | NZ270985A (fr) |
PE (1) | PE27997A1 (fr) |
PL (1) | PL308334A1 (fr) |
RU (1) | RU95106649A (fr) |
ZA (1) | ZA953311B (fr) |
Families Citing this family (73)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AU5966096A (en) * | 1995-06-09 | 1997-01-09 | Eli Lilly And Company | Methods of treating cold and allergic rhinitis |
US5849759A (en) * | 1995-12-08 | 1998-12-15 | Berlex Laboratories, Inc. | Naphthyl-substituted benzimidazole derivatives as anti-coagulants |
EP0891334A1 (fr) | 1996-04-03 | 1999-01-20 | Merck & Co., Inc. | Inhibiteurs de la farnesyl-proteine transferase |
JP3271991B2 (ja) | 1997-11-07 | 2002-04-08 | 大鵬薬品工業株式会社 | ベンズイミダゾール誘導体及びその薬学的に許容される塩 |
US7163949B1 (en) | 1999-11-03 | 2007-01-16 | Amr Technology, Inc. | 4-phenyl substituted tetrahydroisoquinolines and use thereof |
BR0015320A (pt) | 1999-11-03 | 2002-07-09 | Albany Molecular Res Inc | Composto, composição, métodos de tratamento de um distúrbio que e criado pela, ou é dependente da, disponibilidade diminuìda de serotonina, norepinefrina ou dopamina, para inibir a captação da serotonina, da dopamina e de norepinefrina sinápticas em um paciente em necessidade destes, e, kit |
US6770666B2 (en) | 1999-12-27 | 2004-08-03 | Japan Tobacco Inc. | Fused-ring compounds and use thereof as drugs |
AU763356C (en) | 1999-12-27 | 2004-08-26 | Japan Tobacco Inc. | Fused-ring compounds and use thereof as drugs |
CZ303726B6 (cs) * | 2000-01-14 | 2013-04-10 | Bayer Intellectual Property Gmbh | Benzimidazolové deriváty, farmaceutický prostredek obsahující tyto deriváty a pouzití techto derivátu pro prípravu léciv |
US7115645B2 (en) * | 2000-01-14 | 2006-10-03 | Schering Aktiengesellschaft | 1,2 diarylbenzimidazoles and their pharmaceutical use |
US7329679B2 (en) | 2000-01-27 | 2008-02-12 | Schering Aktiengesellschaft | 1,2 Diarylbenzimidazoles and their pharmaceutical use |
US7084152B2 (en) | 2000-07-11 | 2006-08-01 | Amr Technology, Inc. | 4-phenyl substituted tetrahydroisoquinolines therapeutic use thereof |
WO2002046168A1 (fr) * | 2000-12-07 | 2002-06-13 | Astrazeneca Ab | Composes therapeutiques de benzimidazole |
RU2003127367A (ru) | 2001-03-12 | 2005-03-20 | Аванир Фармасьютиклз (Us) | Бензимидазоловые соединения для модулирования ige и ингибирования клеточной пролиферации |
US7405235B2 (en) | 2001-05-04 | 2008-07-29 | Paratek Pharmaceuticals, Inc. | Transcription factor modulating compounds and methods of use thereof |
UA83620C2 (ru) | 2001-12-05 | 2008-08-11 | Уайт | Замещенные бензоксазолы и их аналоги как эстрогенные агенты |
US6962932B2 (en) | 2002-02-15 | 2005-11-08 | Schering Aktiengesellschaft | 1-phenyl-2-heteroaryl-substituted benzimdazole derivatives, their use for the production of pharmaceutical agents as well as pharmaceutical preparations that contain these derivatives |
ES2549159T3 (es) | 2002-03-13 | 2015-10-23 | Array Biopharma, Inc. | Derivados de bencimidazol N3-alquilados como inhibidores de MEK |
AU2003251944B2 (en) | 2002-07-15 | 2008-06-26 | Myriad Genetics, Inc. | Compounds, compositions, and methods employing same |
DE10238002A1 (de) * | 2002-08-20 | 2004-03-04 | Merck Patent Gmbh | Benzimidazolderivate |
TWI276631B (en) | 2002-09-12 | 2007-03-21 | Avanir Pharmaceuticals | Phenyl-aza-benzimidazole compounds for modulating IgE and inhibiting cellular proliferation |
AU2003270426A1 (en) | 2002-09-12 | 2004-04-30 | Avanir Pharmaceuticals | PHENYL-INDOLE COMPOUNDS FOR MODULATING IgE AND INHIBITING CELLULAR PROLIFERATION |
DE10248925A1 (de) * | 2002-10-15 | 2004-04-29 | Proteosys Ag | Neue Verbindungen mit dopaminerger und/oder serotoninerger Aktivität |
JP2007501189A (ja) | 2003-08-01 | 2007-01-25 | ジェネラブス テクノロジーズ,インコーポレイテッド | フラビウイルス科に対する二環式イミダゾール誘導体 |
WO2005081687A2 (fr) * | 2003-09-30 | 2005-09-09 | Centocor, Inc. | Mimeticorps de noyau-charniere humain, compositions, procedes et applications correspondantes |
JP2008504233A (ja) | 2004-04-23 | 2008-02-14 | パラテック ファーマシューティカルズ インコーポレイテッド | 転写因子調節化合物およびその使用法 |
CA2573271C (fr) | 2004-07-15 | 2015-10-06 | Amr Technology, Inc. | Tetrahydroisoquinolines a substitution aryle et heteroaryle et leur utilisation pour bloquer le recaptage de la norepinephrine, la dopamine et la serotonine |
DE102005012873B4 (de) | 2005-03-19 | 2007-05-03 | Sanofi-Aventis Deutschland Gmbh | Aminocarbonyl substituierte 8-N-Benzimidazole, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel |
EP1888050B1 (fr) | 2005-05-17 | 2012-03-21 | Merck Sharp & Dohme Ltd. | Acide cis-4-[(4-chlorophenyl)sulfonyl]-4-(2,5-difluorophenyl) cyclohexanepropanoique pour le traitement du cancer |
JP5258561B2 (ja) | 2005-07-15 | 2013-08-07 | アルバニー モレキュラー リサーチ, インコーポレイテッド | アリール置換およびヘテロアリール置換テトラヒドロベンズアゼピンならびにノルエピネフリン、ドーパミンおよびセロトニンの再取り込みを遮断するためのその使用 |
GB0603041D0 (en) | 2006-02-15 | 2006-03-29 | Angeletti P Ist Richerche Bio | Therapeutic compounds |
US20110218176A1 (en) | 2006-11-01 | 2011-09-08 | Barbara Brooke Jennings-Spring | Compounds, methods, and treatments for abnormal signaling pathways for prenatal and postnatal development |
MX2009007200A (es) | 2007-01-10 | 2009-07-15 | Angeletti P Ist Richerche Bio | Indazoles sustituidos con amida como inhibidores de poli(adp-ribosa)polimerasa (parp). |
AU2008269154B2 (en) | 2007-06-27 | 2014-06-12 | Merck Sharp & Dohme Llc | 4-carboxybenzylamino derivatives as histone deacetylase inhibitors |
US9149463B2 (en) | 2007-09-18 | 2015-10-06 | The Board Of Trustees Of The Leland Standford Junior University | Methods and compositions of treating a Flaviviridae family viral infection |
US9101628B2 (en) | 2007-09-18 | 2015-08-11 | The Board Of Trustees Of The Leland Stanford Junior University | Methods and composition of treating a flaviviridae family viral infection |
US8895598B2 (en) | 2007-09-18 | 2014-11-25 | The Board Of Trustees Of The Leland Stanford Junior University | Methods of treating a flaviviridae family viral infection, compositions for treating a flaviviridae family viral infection, and screening assays for identifying compositions for treating a flaviviridae family viral infection |
US8940730B2 (en) | 2007-09-18 | 2015-01-27 | The Board Of Trustees Of The Leland Stanford Junior University | Methods and compositions of treating a Flaviviridae family viral infection |
DK2280706T3 (da) | 2008-05-14 | 2013-02-04 | Otsuka Pharma Co Ltd | Lipasa-aktiverende lipoproteinsammensætninger omfattende benzenderivater |
AR071997A1 (es) | 2008-06-04 | 2010-07-28 | Bristol Myers Squibb Co | Forma cristalina de 6-((4s)-2-metil-4-(2-naftil)-1,2,3,4-tetrahidroisoquinolin-7-il)piridazin-3-amina |
US9156812B2 (en) | 2008-06-04 | 2015-10-13 | Bristol-Myers Squibb Company | Crystalline form of 6-[(4S)-2-methyl-4-(2-naphthyl)-1,2,3,4-tetrahydroisoquinolin-7-yl]pyridazin-3-amine |
CN102448458B (zh) | 2009-03-18 | 2015-07-22 | 小利兰·斯坦福大学理事会 | 治疗黄病毒科病毒感染的方法和组合物 |
WO2010114780A1 (fr) | 2009-04-01 | 2010-10-07 | Merck Sharp & Dohme Corp. | Inhibiteurs de l'activité akt |
WO2010132437A1 (fr) | 2009-05-12 | 2010-11-18 | Albany Molecular Research, Inc. | Aryle, hétéroaryle et tétrahydroisoquinolines à hétérocycle substitué et leur utilisation |
AU2010247763B2 (en) | 2009-05-12 | 2015-12-24 | Albany Molecular Research, Inc. | 7-([1,2,4,]triazolo[1,5,-a]pyridin-6-yl)-4-(3,4-dichlorophenyl)-1,2,3,4- tetrahydroisoquinoline and use thereof |
KR20120023072A (ko) | 2009-05-12 | 2012-03-12 | 브리스톨-마이어스 스큅 컴퍼니 | (S)-7-(〔1,2,4〕트리아졸〔1,5-a〕피리딘-6-일)-4-(3,4-디클로로페닐)-1,2,3,4-테트라하이드로이소퀴놀린의 결정형 및 이의 용도 |
EA023838B1 (ru) | 2009-10-14 | 2016-07-29 | Мерк Шарп Энд Домэ Корп. | ЗАМЕЩЕННЫЕ ПИПЕРИДИНЫ, КОТОРЫЕ ПОВЫШАЮТ АКТИВНОСТЬ p53, И ИХ ПРИМЕНЕНИЕ |
WO2012018754A2 (fr) | 2010-08-02 | 2012-02-09 | Merck Sharp & Dohme Corp. | Inhibition à médiation par interférence arn de caténine (protéine associée à cadhérine), expression du gène bêta 1 (ctnnb1) à l'aide de petit acide nucléique interférent (sian) |
CA2807307C (fr) | 2010-08-17 | 2021-02-09 | Merck Sharp & Dohme Corp. | Inhibition mediee par des arn interferents de l'expression genique du virus de l'hepatite b (vhb) a l'aide de petits acides nucleiques interferents (pani) |
EP2608669B1 (fr) | 2010-08-23 | 2016-06-22 | Merck Sharp & Dohme Corp. | Nouveaux dérivés de pyrazolo[1,5-a]pyrimidine utilisés comme inhibiteurs de mtor |
US8946216B2 (en) | 2010-09-01 | 2015-02-03 | Merck Sharp & Dohme Corp. | Indazole derivatives useful as ERK inhibitors |
EP2615916B1 (fr) | 2010-09-16 | 2017-01-04 | Merck Sharp & Dohme Corp. | Dérivés condensés de pyrazole utilisés comme nouveaux inhibiteurs erk |
NZ608069A (en) | 2010-10-06 | 2014-06-27 | Glaxosmithkline Llc | Benzimidazole derivatives as pi3 kinase inhibitors |
US9260471B2 (en) | 2010-10-29 | 2016-02-16 | Sirna Therapeutics, Inc. | RNA interference mediated inhibition of gene expression using short interfering nucleic acids (siNA) |
EP2654748B1 (fr) | 2010-12-21 | 2016-07-27 | Merck Sharp & Dohme Corp. | Dérivés d'indazole utiles en tant qu'inhibiteurs de erk |
CA2831710A1 (fr) | 2011-03-31 | 2012-10-04 | Bayer Intellectual Property Gmbh | Benzimidazoles substitues servant d'inhibiteurs de mps-1 kinase |
AU2012245971A1 (en) | 2011-04-21 | 2013-10-17 | Piramal Enterprises Limited | A crystalline form of a salt of a morpholino sulfonyl indole derivative and a process for its preparation |
US9023865B2 (en) | 2011-10-27 | 2015-05-05 | Merck Sharp & Dohme Corp. | Compounds that are ERK inhibitors |
EP3453762B1 (fr) | 2012-05-02 | 2021-04-21 | Sirna Therapeutics, Inc. | Compositions d'acide nucléique interférent court (sina) |
JP6280554B2 (ja) | 2012-09-28 | 2018-02-14 | メルク・シャープ・アンド・ドーム・コーポレーションMerck Sharp & Dohme Corp. | Erk阻害剤である新規化合物 |
ME02925B (fr) | 2012-11-28 | 2018-04-20 | Merck Sharp & Dohme | Compositions et procédés pour traiter le cancer |
TW201429969A (zh) | 2012-12-20 | 2014-08-01 | Merck Sharp & Dohme | 作爲hdm2抑制劑之經取代咪唑吡啶 |
EP2951180B1 (fr) | 2013-01-30 | 2018-05-02 | Merck Sharp & Dohme Corp. | Purines 2,6,7,8-substituées utilisées en tant qu'inhibiteurs de hdm2 |
US20160194368A1 (en) | 2013-09-03 | 2016-07-07 | Moderna Therapeutics, Inc. | Circular polynucleotides |
CN104072425B (zh) * | 2014-07-09 | 2016-12-07 | 大连理工大学 | 苯并咪唑类化合物及其应用 |
CN105837522A (zh) * | 2016-06-14 | 2016-08-10 | 绍兴文理学院 | 一种1,5-苯并二氮卓酮衍生物的制备方法 |
GB201617630D0 (en) | 2016-10-18 | 2016-11-30 | Cellcentric Ltd | Pharmaceutical compounds |
CN110536890B (zh) | 2017-04-26 | 2023-08-15 | 巴斯利尔药物国际股份公司 | 制备呋咱并苯并咪唑及其晶型的方法 |
WO2019094311A1 (fr) | 2017-11-08 | 2019-05-16 | Merck Sharp & Dohme Corp. | Inhibiteurs de prmt5 |
GB201806320D0 (en) | 2018-04-18 | 2018-05-30 | Cellcentric Ltd | Process |
US11993602B2 (en) | 2018-08-07 | 2024-05-28 | Merck Sharp & Dohme Llc | PRMT5 inhibitors |
EP3833667B1 (fr) | 2018-08-07 | 2024-03-13 | Merck Sharp & Dohme LLC | Inhibiteurs de prmt5 |
CN111004183B (zh) * | 2019-12-27 | 2022-04-22 | 阜阳欣奕华材料科技有限公司 | 一种有机电致发光化合物、电子传输材料和有机电致发光器件 |
Family Cites Families (15)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB1174493A (en) * | 1967-05-10 | 1969-12-17 | Manufactures J R Bottu | New Benzimidazoles and process for their preparation |
JPS50126682A (fr) | 1974-03-25 | 1975-10-04 | ||
US4200641A (en) | 1976-12-21 | 1980-04-29 | Janssen Pharmaceutica, N.V. | 1-[(Heterocyclyl)-alkyl]-4-diarylmethoxy piperidine derivatives |
EP0178413A1 (fr) | 1984-08-17 | 1986-04-23 | Beecham Group Plc | Benzimidazoles |
US5023252A (en) | 1985-12-04 | 1991-06-11 | Conrex Pharmaceutical Corporation | Transdermal and trans-membrane delivery of drugs |
FR2597478B1 (fr) | 1986-04-21 | 1988-12-16 | Esteve Labor Dr | Benzimidazoles et imidazopyridines sulfonamides, leur preparation et leur application en tant que medicaments. |
DE3728695A1 (de) | 1987-08-25 | 1989-03-09 | Schering Ag | Neue benzimidazol-derivate |
DE3800096A1 (de) | 1988-01-05 | 1989-07-13 | Bayer Ag | Verwendung von benzimidazolderivaten als leistungsfoerderer |
US5011472A (en) | 1988-09-06 | 1991-04-30 | Brown University Research Foundation | Implantable delivery system for biological factors |
JPH0772181B2 (ja) * | 1989-06-26 | 1995-08-02 | 株式会社大塚製薬工場 | ベンズイミダゾール誘導体 |
FR2665161B1 (fr) | 1990-07-26 | 1992-11-27 | Esteve Labor Dr | Nouveaux derives de benzimidazole, leur preparation et leur application en tant que medicaments. |
WO1994004494A1 (fr) | 1992-08-13 | 1994-03-03 | Warner-Lambert Company | Antagonistes de tachykinine |
US5472978A (en) | 1991-07-05 | 1995-12-05 | Merck Sharp & Dohme Ltd. | Aromatic compounds, pharmaceutical compositions containing them and their use in therapy |
US5612336A (en) | 1992-07-13 | 1997-03-18 | Merck, Sharp & Dohme Ltd. | Heterocyclic amide derivatives as tachykinin antagonists |
FR2696178B1 (fr) | 1992-09-30 | 1994-12-30 | Sanofi Elf | Amides basiques quaternaires, procédé pour leur préparation et compositions pharmaceutiques en contenant. |
-
1995
- 1995-04-24 IL IL11347295A patent/IL113472A0/xx unknown
- 1995-04-24 CZ CZ951047A patent/CZ104795A3/cs unknown
- 1995-04-24 NZ NZ270985A patent/NZ270985A/en unknown
- 1995-04-24 ZA ZA953311A patent/ZA953311B/xx unknown
- 1995-04-24 PE PE1995266991A patent/PE27997A1/es not_active Application Discontinuation
- 1995-04-24 EP EP95302707A patent/EP0694535A1/fr not_active Withdrawn
- 1995-04-25 PL PL95308334A patent/PL308334A1/xx unknown
- 1995-04-25 BR BR9501770A patent/BR9501770A/pt not_active Application Discontinuation
- 1995-04-26 CO CO95017350A patent/CO4560552A1/es unknown
- 1995-04-26 AU AU17656/95A patent/AU1765695A/en not_active Abandoned
- 1995-04-26 CN CN95104725A patent/CN1113236A/zh active Pending
- 1995-04-27 CA CA002148053A patent/CA2148053A1/fr not_active Abandoned
- 1995-04-27 KR KR1019950010020A patent/KR950031074A/ko not_active Application Discontinuation
- 1995-04-27 RU RU95106649/04A patent/RU95106649A/ru unknown
- 1995-04-27 NO NO951613A patent/NO951613L/no unknown
- 1995-04-28 JP JP7105297A patent/JPH08109169A/ja not_active Withdrawn
- 1995-04-28 HU HU9501249A patent/HUT70637A/hu unknown
- 1995-04-28 FI FI952064A patent/FI952064A/fi unknown
Also Published As
Publication number | Publication date |
---|---|
RU95106649A (ru) | 1997-01-10 |
BR9501770A (pt) | 1995-11-21 |
JPH08109169A (ja) | 1996-04-30 |
CO4560552A1 (es) | 1998-02-10 |
HUT70637A (en) | 1995-10-30 |
PL308334A1 (en) | 1995-10-30 |
KR950031074A (ko) | 1995-12-18 |
CA2148053A1 (fr) | 1995-10-30 |
NZ270985A (en) | 1997-06-24 |
IL113472A0 (en) | 1995-07-31 |
NO951613D0 (no) | 1995-04-27 |
FI952064A0 (fi) | 1995-04-28 |
FI952064A (fi) | 1995-10-30 |
CN1113236A (zh) | 1995-12-13 |
ZA953311B (en) | 1996-10-24 |
AU1765695A (en) | 1995-11-09 |
HU9501249D0 (en) | 1995-06-28 |
PE27997A1 (es) | 1997-09-20 |
CZ104795A3 (en) | 1996-02-14 |
EP0694535A1 (fr) | 1996-01-31 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
NO951613L (no) | Ikke-peptidyl tachykinin reseptorantagonister | |
MXPA99001870A (es) | Antagonistas del receptor de taquicinina,no peptidicos. | |
NO960630D0 (no) | Heterocykler anvendelige som neurokinin antagonister | |
MX9703186A (es) | Antagonistas del receptor del neuropeptido y de indolilo. | |
EE9900481A (et) | Väikesed molekulid, mida kasutatakse põletikuliste haiguste raviks | |
LU91758I2 (fr) | Denosumab et ses dérivés pharmaceutiquement acceptables (PROLIA®) | |
NO981944D0 (no) | Lipopolyaminer som transfeksjonsmidler samt farmas÷ytisk anvendelse derav | |
NO180538C (no) | N-sulfonyl-2-oksoindol-derivater som har affinitet for vasopressin- og/eller ocytocin-reseptorer, farmasöytiske blandinger som inneholder dem og mellomprodukter ved fremstilling av derivatene | |
EA199800140A1 (ru) | Композиции с контролируемым высвобождением пароксетина | |
NO306210B1 (no) | Ikke-peptid tachykinin reseptorantagonister | |
ES2154674T3 (es) | Derivados de 1,5-benzodiacepinas con actividad antagonista o agonista de cck. | |
SE9301667D0 (sv) | New use | |
MX9201356A (es) | Derivados de piperidina, procedimiento para su preparacion y composicion farmaceutica que los contiene. | |
DK0556332T3 (da) | Substituerede tetrahydropyridiner og hydroxypiperidiner som midler til behandling af centralnervesystemet | |
HUP0103203A2 (hu) | Azaadamantánszármazékok és ezeket tartalmazó gyógyszerkészítmények | |
ATE148989T1 (de) | Partielle agonisten der strychnin unempfindlichen glycinmodulierenden stelle des n-methyl-d- aspartat-rezeptor-komplexes als neuropsycho- pharmakologische wirkstoffe | |
TR199700956T1 (xx) | Indazolkarboksamidler. | |
EA199800867A1 (ru) | Соединения тетрагидробетакарболина | |
NO20000519L (no) | 2-acylaminopropanaminer som takykininreseptorantagonister | |
ES2099865T3 (es) | Ciclopentanoperhidrofenantreno-17beta-(3-furil)-3-derivados y composiciones farmaceuticas que comprenden los mismos para el tratamiento de trastornos cardiovasculares. | |
EA199800610A1 (ru) | Способ создания физиологически активных соединений | |
EA199700243A1 (ru) | Производное аминотетралина для лечения сердечно-сосудистых заболеваний | |
DE69431662T2 (de) | Stabilisierte tablettenformulierung | |
PT1001942E (pt) | Poli-hidroxibutilpirazinas sua preparacao e medicamentos que as contem | |
DK0457215T3 (da) | 3-deamino-4-desoxy-4-amino-8-fluoranthracycliner samt fremgangsmåder til fremstilling deraf |